# Clinical Trials Data KIT - Document 26

# Study of Hemospray for Lower Gastrointestinal Hemorrhage

## Clinical Trial: https://clinicaltrials.gov/study/NCT02099435

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patient in which Hemospray is used to treat an endoscopically confirmed nonvariceal lower GI bleed requiring hemostasis\n\nExclusion Criteria:\n\n\* Less than 19 years old\n\* Unwilling or unable to sign and date the informed consent\n\* Pregnant, lactating or planning to become pregnant within 30 days of the procedure\n\* Contraindicated to undergo colonoscopy\n\nMedical/Endoscopic Exclusion Criteria\n\n\* Actual or suspected lower GI perforation or fistula\n\* Bleeding originating from inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)\n\* Actual or suspected ischemic colitis or infectious colitis\n\* Unable to visualize site of active bleeding (such as suspected diverticular bleed where source is unable to be identified)\n\* Unable to treat active site of bleeding (e.g., bleeding site cannot be reached by the colonoscope)",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "19 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "clinical sites",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention anything about KIT gene mutations as an inclusion or exclusion criterion. Therefore, having a KIT gene mutation \*\*doesn't automatically exclude\*\* a patient from this trial.   
  
However, the patient still needs to meet \*all\* other inclusion criteria and \*not\* meet any exclusion criteria to be eligible. The presence of the KIT mutation itself is irrelevant based on this description.